Xiang-dong GUAN, Zi-meng LIU. Maintenance of Perfusion Pressure: How to Choose the Vasoconstriction Drugs?[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 456-460. doi: 10.3969/j.issn.1674-9081.2019.05.006
Citation: Xiang-dong GUAN, Zi-meng LIU. Maintenance of Perfusion Pressure: How to Choose the Vasoconstriction Drugs?[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 456-460. doi: 10.3969/j.issn.1674-9081.2019.05.006

Maintenance of Perfusion Pressure: How to Choose the Vasoconstriction Drugs?

doi: 10.3969/j.issn.1674-9081.2019.05.006
More Information
  • Corresponding author: GUAN Xiang-dong Tel: 86-20-87755766, E-mail:guanxiangdong1962@163.com
  • Received Date: 2019-07-11
  • Publish Date: 2019-09-30
  • Shock is a common critical condition of numerous diseases, resulting in multi-organ dysfunction and death. Vasopressors are the essential part of shock management. Catecholamines are the most commonly used vasopressors in the intensive care unit, among which norepinephrine is the first-line therapy in most clinical conditions. Vasopressin and angiotensin Ⅱ may be useful owing to their norepinephrine-sparing effects. Careful selection of vasoconstriction drugs based on desired pharmacologic effects that are matched to the patient's underlying pathophysiology of shock may optimize hemodynamics while reducing the potential for adverse effects.
  • loading
  • [1] Mayr VD, Dunser MW, Greil V, et al. Causes of death and determinants of outcome in critically ill patients[J]. Crit Care, 2006, 10:R154. doi:  10.1186/cc5086
    [2] De Backer D, Foulon P. Minimizing catecholamines and optimizing perfusion[J].Crit Care, 2019, 23:149. doi:  10.1186/s13054-019-2433-6
    [3] Jentzer JC, Coons JC, Link CB, et al. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit[J]. J Cardiovasc Pharmacol Ther, 2015, 20:249-246. doi:  10.1177/1074248414559838
    [4] Annane D, Ouanes-Besbes L, de Backer D, et al. A global perspective on vasoactive agents in shock[J]. Intensive Care Med, 2018, 44:833-846. doi:  10.1007/s00134-018-5242-5
    [5] De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock[J]. N Engl J Med, 2010, 362:779-789. doi:  10.1056/NEJMoa0907118
    [6] Hamzaoui O, Jozwiak M, Geffriaud T, et al. Norepinephrine exerts an inotropic effect at the early phase of human septic shock[J]. Br J Anaesth, 2018, 120:517-524. doi:  10.1016/j.bja.2017.11.065
    [7] De Backer D, Pinsky M. Norepinephrine improves cardiac function during septic shock, but why?[J].Br J Anaesth, 2018, 120:421-424. doi:  10.1016/j.bja.2017.11.069
    [8] Albanese J, Leone M, Garnier F, et al. Renal effects of norepinephrine in septic and nonseptic patients[J]. Chest, 2004, 126:534-539. doi:  10.1378/chest.126.2.534
    [9] Boerma EC, Ince C. The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients[J]. Intensive Care Med, 2010, 36:2004-2018. doi:  10.1007/s00134-010-1970-x
    [10] Hamzaoui O, Scheeren TWL, Teboul JL.Norepinephrine in septic shock:when and how much?[J].Curr Opin Crit Care, 2017, 23:342-347. doi:  10.1097/MCC.0000000000000418
    [11] Martin C, Medam S, Antonini F, et al. Norepinephrine:not too much, too long[J]. Shock, 2015, 44:305-309. doi:  10.1097/SHK.0000000000000426
    [12] Tanja A, Treschan MD, Peters MD. The Vasopressin System[J].Anesthesiology, 2006, 105:599-612 doi:  10.1097/00000542-200609000-00026
    [13] Holmes CL, Landry DW, Granton JT. Science review:vasopressin and the cardiovascular system part 1-receptor physiology[J]. Crit Care, 2003, 7:427-434. doi:  10.1186/cc2337
    [14] James A, Russell MD, Keith R, et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock[J].N Engl J Med, 2008, 358:877-887. doi:  10.1056/NEJMoa067373
    [15] Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign:international guidelines for management of sepsis and septicshock:2016[J]. Intensive Care Med, 2017, 43:304-377. doi:  10.1007/s00134-017-4683-6
    [16] Marks JA, Pascual JL. Selepressin in septic shock:Sharpening the VASST effects of vasopressin?[J].Crit Care Med, 2014, 42:1747-1748. doi:  10.1097/CCM.0000000000000420
    [17] Liu ZM, Chen J, Kou QY, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock:a multicentre, randomised, double-blinded trial[J].Intensive Care Med, 2018, 44:1816-1825. doi:  10.1007/s00134-018-5267-9
    [18] Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock:the vanish randomized clinical trial[J]. JAMA, 2016, 316:509-518. doi:  10.1001/jama.2016.10485
    [19] Scheeren TWL, Bakker J, De Backer D, et al. Current use of vasopressors in septic shock[J]. Ann Intensive Care, 2019, 9:20. doi:  10.1186/s13613-019-0498-7
    [20] Dietrich A, Mathia S, Kaminski H, et al. Chronic activation of vasopressin V2 receptor signalling lowers renal medullary oxygen levels in rats[J]. Acta Physiol (Oxf), 2013, 207:721-731. doi:  10.1111/apha.12067
    [21] Qiu X, Huang Y, Xu J, et al.Effects of terlipressin on microcirculation of small bowel mesentery in rats with endotoxic shock[J].J Surg Res, 2014, 188:503-509. http://www.ncbi.nlm.nih.gov/pubmed/24582066
    [22] Hall A, Busse LW, Ostermann M. Angiotensin in Critical Care[J]. Crit Care, 2018, 22:69. http://www.researchgate.net/publication/324074837_Angiotensin_in_Critical_Care
    [23] Khanna A, English SW, Wang XS, et al. Angiotensin Ⅱ for the Treatment of Vasodilatory Shock[J]. N Engl J Med, 2017, 377:419-430. http://www.onacademic.com/detail/journal_1000040154977810_2eaf.html
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索


    Article Metrics

    Article views (1764) PDF downloads(275) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint